These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38958425)

  • 61. Barriers and facilitators to implementing medications for opioid use disorder and naloxone distribution in Veterans Affairs emergency departments.
    Sasson C; Dieujuste N; Klocko R; Basrai Z; Celedon M; Hsiao J; Himstreet J; Hoffman J; Pfaff C; Malmstrom R; Smith J; Holstein A; Johnson-Koenke R
    Acad Emerg Med; 2023 Apr; 30(4):289-298. PubMed ID: 36757683
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Losing the uphill battle? Emergent harm reduction interventions and barriers during the opioid overdose crisis in Canada.
    Strike C; Watson TM
    Int J Drug Policy; 2019 Sep; 71():178-182. PubMed ID: 30975595
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Community-level determinants of stakeholder perceptions of community stigma toward people with opioid use disorders, harm reduction services and treatment in the HEALing Communities Study.
    Davis A; Stringer KL; Drainoni ML; Oser CB; Knudsen HK; Aldrich A; Surratt HL; Walker DM; Gilbert L; Downey DL; Gardner SD; Tan S; Lines LM; Vandergrift N; Mack N; Holloway J; Lunze K; McAlearney AS; Huerta TR; Goddard-Eckrich DA; El-Bassel N
    Int J Drug Policy; 2023 Dec; 122():104241. PubMed ID: 37890391
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A naloxone and harm reduction educational program across four years of a doctor of pharmacy program.
    Maguire MA; Pavlakos RN; Mehta BH; Schmuhl KK; Beatty SJ
    Curr Pharm Teach Learn; 2018; 10(1):72-77. PubMed ID: 29248078
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Naloxone Counseling for Harm Reduction and Patient Engagement.
    Han JK; Hill LG; Koenig ME; Das N
    Fam Med; 2017 Oct; 49(9):730-733. PubMed ID: 29045991
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Take-home naloxone in Australia and beyond.
    Olsen A; Dwyer R; Lenton S
    Drug Alcohol Rev; 2018 May; 37(4):437-439. PubMed ID: 29744978
    [No Abstract]   [Full Text] [Related]  

  • 67. Impact of a statewide community pharmacy approach to opioid harm reduction.
    Sexton SM; Marciniak MW; Gatton O; Shelton P
    J Am Pharm Assoc (2003); 2023; 63(1):389-395.e1. PubMed ID: 36369073
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Caring for Hospitalized Adults With Opioid Use Disorder in the Era of Fentanyl: A Review.
    Englander H; Thakrar AP; Bagley SM; Rolley T; Dong K; Hyshka E
    JAMA Intern Med; 2024 Jun; 184(6):691-701. PubMed ID: 38683591
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Where Next for Opioids and the Law? Despair, Harm Reduction, Lawsuits, and Regulatory Reform.
    Burris S
    Public Health Rep; 2018; 133(1):29-33. PubMed ID: 29233069
    [No Abstract]   [Full Text] [Related]  

  • 70. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review.
    Krawczyk N; Fawole A; Yang J; Tofighi B
    Addict Sci Clin Pract; 2021 Nov; 16(1):68. PubMed ID: 34774106
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The missing link: Incorporating behaviour change theories in overdose education and naloxone distribution programs.
    Perri M; Strike C
    Int J Drug Policy; 2020 Sep; 83():102853. PubMed ID: 32688261
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Low Barrier Tele-Buprenorphine in the Time of COVID-19: A Case Report.
    Harris M; Johnson S; Mackin S; Saitz R; Walley AY; Taylor JL
    J Addict Med; 2020; 14(4):e136-e138. PubMed ID: 32433364
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Economic Evaluation of Interventions to Address Opioid Misuse: A Systematic Review of Methods Used in Simulation Modeling Studies.
    Barbosa C; Dowd WN; Zarkin G
    Value Health; 2020 Aug; 23(8):1096-1108. PubMed ID: 32828223
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Barriers and Facilitators to Harm Reduction for Opioid Use Disorder: A Qualitative Study of People With Lived Experience.
    Westafer LM; Beck SA; Simon C; Potee B; Soares WE; Schoenfeld EM
    Ann Emerg Med; 2024 Apr; 83(4):340-350. PubMed ID: 38180403
    [TBL] [Abstract][Full Text] [Related]  

  • 75. High risk and little knowledge: overdose experiences and knowledge among young adult nonmedical prescription opioid users.
    Frank D; Mateu-Gelabert P; Guarino H; Bennett A; Wendel T; Jessell L; Teper A
    Int J Drug Policy; 2015 Jan; 26(1):84-91. PubMed ID: 25151334
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A Rapid Review of the Impact of Systems-Level Policies and Interventions on Population-Level Outcomes Related to the Opioid Epidemic, United States and Canada, 2014-2018.
    Ansari B; Tote KM; Rosenberg ES; Martin EG
    Public Health Rep; 2020; 135(1_suppl):100S-127S. PubMed ID: 32735190
    [TBL] [Abstract][Full Text] [Related]  

  • 77. 'It's the same thing as giving them CPR training': rural first responders' perspectives on naloxone.
    Filteau MR; Green B; Kim F; McBride KA
    Harm Reduct J; 2022 Oct; 19(1):111. PubMed ID: 36192736
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities.
    McCarty D; Priest KC; Korthuis PT
    Annu Rev Public Health; 2018 Apr; 39():525-541. PubMed ID: 29272165
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Reducing the health consequences of opioid addiction in primary care.
    Bowman S; Eiserman J; Beletsky L; Stancliff S; Bruce RD
    Am J Med; 2013 Jul; 126(7):565-71. PubMed ID: 23664112
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dancing with Deterrents: Understanding the Role of Abuse-Deterrent Opioid Formulations and Naloxone in Managing Cancer Pain.
    Mitchell MT
    Oncologist; 2019 Dec; 24(12):1505-1509. PubMed ID: 31152083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.